Skip to search boxSkip to navigationSkip to main content

Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFα expression in transgenic mice

  • Wen Xie
    ,
  • Louise T. Chow
    ,
  • Andrew J. Paterson
    ,
  • Edward Chin
    ,
  • Jeffrey E. Kudlow(corresponding author)
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

The ErbB2 receptor tyrosine kinase (RTK) is expressed in basal cells of squamous epithelia and the outer root sheath of hair follicles. We previously showed that constitutive expression of activated ErbB2 directed to these sites in the skin by the keratin 14 (K14) promoter produces prominent hair follicle abnormalities and striking skin hyperplasia in transgenic mice. However, perinatal lethality precluded the establishment of a transgenic line for analysis of ErbB2 function in adult animals. To investigate the significance of ErbB2 signaling in epithelial tissues during and post development, we developed a K14-rtTA/TetRE-ErbB2 'Tet-On' bitransgenic mouse system. These mice were normal until the ErbB2 transgene was induced by exposure to doxycycline (Dox). Prenatal induction resulted in perinatal death. Postnatally, ErbB2 transgene expression was observed at 4 h after the initiation of Dox, and reached a plateau at 24 h. Skin hyperplasia followed after 2 days and these changes reverted to normal upon Dox withdrawal. In adults, as in the neonates, prolonged ErbB2 induction caused prominent skin and hair follicle hyperplasias. Severe hyperplasias in the cornea, eye lids, tongue and esophagus were also observed. ErbB2 transgene induction was accompanied by increased expression of TGFα, a ligand of epidermal growth factor receptor (EGFR), and to a lesser extent, EGFR, further enhancing RTK signal transduction. We conclude that ErbB2 plays important roles in both development and maintenance of hair follicles and diverse squamous epithelia and that this ligand-inducible and tissue-specific 'Tet-On' transgenic mouse system provides a means to study transgenes with perinatal toxicity.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 3593-3607 (15 pages)

Journal (Volume, Issue Number)

Oncogene (Volume 18, Issue 24)

Publication milestones

  • Published - 06/17/1999

Publication status

Published - 06/17/1999

ISSN

0950-9232

Publication IDs

  • Scopus: 0033578067
  • PubMed: 10380881

Publication metrics

Metrics

SciVal
FWCI
1.70
SciVal
Author count
5
SciVal
citations
114
SciVal
Paper percentile
94
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.20
Fractional count
4
Fractional count
0.80
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
131
Captures
42

Funding Details

This work was supported by Public Health Service Grant DK48882 and DK43652 from the National Institutes of Health (to JE Kudlow) and LT Chow is supported by USPHS grant CA36200. The authors wish to thank Dr WR Staggers for cloning of K14 promoter, Dr P Jolicoeur for ErbB2 cDNA, and J Clark for his help in developing Dox administration protocol.
FundersFunding numbers
NIH
-
NIDDK
R01DK043652
USPHS
CA36200, DK48882